Jiangxi Institute of Biological Products Inc. (Jiangxi Bio) announced that its wholly owned subsidiary, Chifeng Bo-en Pharmaceutical Co., Ltd., has secured the Approval Certificate of Veterinary Drug Product for its veterinary tetanus antitoxin.

The newly approved product is designed to prevent and treat tetanus in animals by providing passive immune protection through toxin neutralisation. Management emphasises that the certification adds a differentiated biologic to the Group’s existing portfolio and establishes a platform for deeper penetration into the animal-health segment.

According to the Board, the licence is expected to enhance Jiangxi Bio’s overall competitiveness and support its long-term development strategy. Shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.